Core Viewpoint - Da An Gene (002030) announced a framework agreement for the acquisition of controlling stakes involving Guangzhou Jin Kong Group, Guangzhou Health Industry Investment, and Guangzhou Pharmaceutical Group [1] Group 1: Acquisition Details - Guangzhou Pharmaceutical Group plans to acquire or designate its wholly-owned subsidiary or related parties to acquire 100% equity of Guangyong Technology held by Guangzhou Jin Kong Group, indirectly controlling 233 million shares of Da An Gene [1] - Additionally, Guangzhou Pharmaceutical Group will acquire 70.1723 million shares of Da An Gene from Guangzhou Jin Kong Group and another 70.1723 million shares from Guangzhou Health Industry Investment through a separate agreement [1] - Upon completion of these transactions, Guangzhou Pharmaceutical Group will control a total of 26.63% of Da An Gene's shares, becoming the indirect controlling shareholder of the company [1] Group 2: Impact on Control - The successful implementation of this transaction will not result in a change of the company's controlling shareholder or actual controller [1]

Core Viewpoint - Da An Gene (002030.SZ) has received notifications from Guangzhou Financial Holdings Group, Guangzhou Health Industry Investment, and Guangzhou Pharmaceutical Group regarding a framework agreement signed on November 15, 2025, for the transfer of shares [1][2] Group 1 - Guangzhou Financial Holdings Group plans to transfer its 100% stake in Guangyong Technology, which includes a 16.63% stake in Da An Gene, along with a 5% stake held by itself and another 5% stake held by Guangzhou Health Industry Investment to Guangzhou Pharmaceutical Group or its designated affiliates [1] - The total consideration for this transaction will be the sum of the transfer price for the equity and the consideration specified in the agreement [1] Group 2 - Before the equity change, Guangzhou Financial Holdings Group was the indirect controlling shareholder of Da An Gene, holding a total of 443,908,904 shares, representing a 31.63% stake [2] - If the equity change is completed, Guangzhou Pharmaceutical Group will become the indirect controlling shareholder, controlling 373,736,601 shares, which is 26.63% of the total share capital, while Guangzhou Financial Holdings Group will retain a 5% stake through Guangzhou Health Industry Investment [2] - The controlling shareholder will remain Guangyong Technology, and the actual controller will still be the Guangzhou Municipal Government, indicating no change in control [2]

关于间接控股股东拟发生变更的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002030 证券简称：达安基因 公告编号：2025-063 广州达安基因股份有限公司 重要内容提示： 1、2025 年 11 月 15 日，广州金融控股集团有限公司（以下简称"广州金控 集团"）、广州生物医药与健康产业投资有限公司（以下简称"广州健康产投"） 与广州医药集团有限公司（以下简称"广药集团"）签署了《关于广州达安基因 股份有限公司控股权收购框架协议》（以下简称"《框架协议》"），广药集团 拟根据《框架协议》项下的条款和条件受让或指定其全资子公司等关联方受让广 州金控集团持有的广州广永科技发展有限公司（以下简称"广永科技"）100% 股权而间接控制广永科技持有的广州达安基因股份有限公司（以下简称"公司" 或"达安基因"）233,391,995 股股份（以下简称"本次股权转让"）；并另行 通过协议转让方式受让广州金控集团持有的达安基因 70,172,302 股股份和广州 健康产投持有的达安基因 70,172,304 股股份（以下简称"本次协议转让"）。若 ...

Group 1 - The core point of the news is that Guangzhou Pharmaceutical Group intends to acquire a controlling stake in Da An Gene, which will result in the group controlling approximately 26.63% of the company's total shares [1] - The acquisition involves Guangzhou Pharmaceutical Group indirectly controlling about 233 million shares of Da An Gene through Guangzhou Guangyong Technology Development Co., Ltd. and acquiring an additional 70.17 million shares from Guangzhou Financial Holdings Group and Guangzhou Health Industry Investment [1] - After the completion of this equity change, the actual controlling shareholder will remain the Guangzhou Municipal Government, with Guangzhou Guangyong Technology still being the controlling shareholder [1] Group 2 - For the first half of 2025, Da An Gene's revenue composition shows that the bioproducts sector accounts for 95.68% of total revenue, while financial services contribute 4.32% [2] - As of the latest report, Da An Gene has a market capitalization of 9.7 billion yuan [3]

证券代码：002030 证券简称：达安基因 公告编号：2025-062 附件：职工代表董事个人简历 陈洁女士的任职资格符合相关法律法规及《公司章程》有关规定。本次选举 后，公司第九届董事会中兼任公司高级管理人员以及由职工代表担任的董事人数 总计未超过公司董事总数的二分之一，符合相关法律法规的要求。 特此公告。 广州达安基因股份有限公司 董 事 会 2025 年 11 月 17 日 广州达安基因股份有限公司 关于选举第九届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为保障广州达安基因股份有限公司（以下简称"公司"）董事会规范运作， 进一步优化治理结构，提高董事会决策的科学性、有效性，结合公司实际情况， 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规和《公司章程》的规定，公司于 2025 年 11 月 17 日召开职工代表大会，经与会职工代表审议表决，选举陈洁女士（简 历详见附件）为公司第九届董事会职工代表董事。陈洁女士与经公司 2025 年第 二次临时股东会选举产生的非 ...

证券代码：002030 证券简称：达安基因 公告编号：2025-061 广州达安基因股份有限公司 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更前次股东会决议。 3、本次股东会以现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 5、会议主持人：公司董事长韦典含女士 6、会议召开的合法、合规性：本次股东会的召开符合《公司法》《深圳证券 交易所股票上市规则》（2025 年修订）等有关法律、行政法规、部门规章、规范 1 性文件和《公司章程》的有关规定。 （二）会议出席情况 本次股东会采取现场投票与网络投票相结合的方式进行投票表决。出席本次 股东会的股东及股东授权委托代表 601 人，代表股份 459,359,691 股，占上市公 司总股份的 32.7308％。其中： （1）现场会议召开时间：2025 年 11 月 17 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间 ...

7. 公司本次股东会议案及涉及相关议案内容的公告等文件； 北京市金杜（广州）律师事务所 关于广州达安基因股份有限公司 2025 年第四次临时股东会的法律意见书 致：广州达安基因股份有限公司 北京市金杜（广州）律师事务所（以下简称本所）接受广州达安基因股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、《上市公司股东会规 则》（以下简称《股东会规则》）等中华人民共和国境内（以下简称中国境内，为 本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别行政区和中国 台湾省）现行有效的法律、行政法规、规章和规范性文件和现行有效的《广州达 安基因股份有限公司公司章程》（以下简称《公司章程》）有关规定，指派律师出 席了公司于 2025 年 11 月 17 日召开的 2025 年第四次临时股东会（以下简称本 次股东会），并就本次股东会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2025 年第三次临时股东会审议通过的《公司章程》； 2. 公司 2025 年 10 月 3 ...

Core Viewpoint - Guangzhou Pharmaceutical Group intends to acquire controlling stakes in Da An Gene, potentially becoming the indirect controlling shareholder with 26.63% of the total share capital [1] Group 1: Acquisition Details - On November 15, 2025, Guangzhou Jin Kong Group, Guangzhou Health Industry Investment, and Guangzhou Pharmaceutical Group signed a framework agreement for the acquisition of Da An Gene's controlling rights [1] - Guangzhou Pharmaceutical Group plans to acquire 100% equity of Guangyong Technology held by Guangzhou Jin Kong Group, which indirectly controls 233 million shares of Da An Gene [1] - Additionally, Guangzhou Pharmaceutical Group will acquire 70.1723 million shares of Da An Gene from both Guangzhou Jin Kong Group and Guangzhou Health Industry Investment through a separate agreement [1] Group 2: Shareholding Impact - Upon completion of the transaction, Guangzhou Pharmaceutical Group will control a total of 374 million shares of Da An Gene, representing 26.63% of the company's total share capital [1]

Core Insights - The medical testing industry is facing significant challenges due to increased accounts receivable and declining profits, particularly following the COVID-19 pandemic [1][4][5] Group 1: Accounts Receivable and Financial Performance - Four companies have accounts receivable exceeding 2 billion yuan, with Capbio (凯普生物) involved in lawsuits to recover 357 million yuan in overdue payments [1] - In the first three quarters of this year, at least seven medical testing companies reported net losses attributable to shareholders, with six of them expected to continue this trend into 2024 [1] - Specific losses reported include: Puni Testing (谱尼测试) at 199 million yuan, RunDa Medical (润达医疗) at 163 million yuan, and Capbio at 128 million yuan [1] Group 2: Impact of Price Reductions and Impairment Provisions - Price reductions in the testing sector have led to widespread profit shrinkage among medical testing companies, with some firms making impairment provisions for accounts receivable [4] - Companies like KingMed Diagnostics (金域医学) have made significant impairment provisions, totaling 345 million yuan, primarily for accounts receivable, which reduced their consolidated profit by the same amount [4] - Lanwei Medical (兰卫医学) reported a total impairment provision of 16.73 million yuan, with 13.50 million yuan specifically for accounts receivable [5] Group 3: Recovery Trends and Future Outlook - The Ministry of Finance has indicated a commitment to debt reduction policies, which may accelerate the collection of accounts receivable from public hospitals [5] - Companies are implementing strategies to manage accounts receivable more effectively, with Puni Testing focusing on tailored collection strategies for major clients [6] - DiAn Diagnostics (迪安诊断) anticipates improved collection trends in the second half of the year, with expectations that all COVID-related accounts receivable will be fully provisioned by year-end [5][6]

证券日报网讯达安基因（002030）11月13日在互动平台回答投资者提问时表示，公司仅提供每月月末股 东人数，截至2025年10月31日，公司股东总户数约为13万9千户。 ...